{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:16:37Z","timestamp":1774869397873,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000268","name":"UK Biotechnology & Biological Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Councils","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.neuropharm.2012.06.011","type":"journal-article","created":{"date-parts":[[2012,6,18]],"date-time":"2012-06-18T14:21:53Z","timestamp":1340029313000},"page":"818-828","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats"],"prefix":"10.1016","volume":"63","author":[{"given":"Gaynor A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludivine S.","family":"Breger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma L.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Dunnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2012.06.011_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ar.1090940210","article-title":"Estimation of nuclear population from microtome sections","volume":"94","author":"Abercrombie","year":"1946","journal-title":"The Anatomical Record"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0306-4522(93)90297-S","article-title":"Dopamine-rich grafts in the neostriatum and\/or nucleus accumbens: effects on drug-induced behaviours and skilled paw-reaching","volume":"53","author":"Abrous","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","article-title":"Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia","volume":"57","author":"Aubert","year":"2005","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0006-8993(79)90472-4","article-title":"Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants","volume":"177","author":"Bjorklund","year":"1979","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neubiorev.2006.03.003","article-title":"Psychoactive drugs and regulation of the cAMP\/PKA\/DARPP-32 cascade in striatal medium spiny neurons","volume":"31","author":"Borgkvist","year":"2007","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0006-8993(86)91316-8","article-title":"The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting","volume":"366","author":"Brundin","year":"1986","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/brain\/awn305","article-title":"Impact of grafted serotonin and dopamine neurons on development of l-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration","volume":"132","author":"Carlsson","year":"2009","journal-title":"Brain: a Journal of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/syn.20527","article-title":"Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat","volume":"62","author":"Carta","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib10","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0925s41","article-title":"Ratings of l-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson\u2019s disease in rats and mice","author":"Cenci","year":"2007","journal-title":"Current Protocols in Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuroscience.2004.10.026","article-title":"Enhanced striatal opioid receptor-mediated G-protein activation in l-DOPA-treated dyskinetic monkeys","volume":"132","author":"Chen","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3340\/jkns.2009.46.1.52","article-title":"Thalamic Deep brain stimulation for Writer\u2019s Cramp","volume":"46","author":"Cho","year":"2009","journal-title":"Journal of Korean Neurosurgical Society"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0014-2999(76)90229-6","article-title":"Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway","volume":"35","author":"Costall","year":"1976","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.tins.2004.03.011","article-title":"DAncing past the DAT at a DA synapse","volume":"27","author":"Cragg","year":"2004","journal-title":"Trends in Neurosciences"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.parkreldis.2005.05.008","article-title":"Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"11","author":"da Silva-Junior","year":"2005","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.brainres.2009.11.009","article-title":"Dopamine D1, D2 and mu-opioid receptors are co-expressed with adenylyl cyclase 5 and phosphodiesterase 7B mRNAs in striatal rat cells","volume":"1310","author":"de Gortari","year":"2010","journal-title":"Brain Research"},{"issue":"1","key":"10.1016\/j.neuropharm.2012.06.011_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/brain\/119.1.41","article-title":"Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach","volume":"119","author":"Defer","year":"1996","journal-title":"Brain: a Journal of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","article-title":"Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson\u2019s disease","volume":"69","author":"Dekundy","year":"2006","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/syn.890040413","article-title":"Distribution of dopamine D1 and D2 receptors in rabbit cortical areas, hippocampus, and neostriatum in relation to dopamine contents","volume":"4","author":"Dewar","year":"1989","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0006-8993(81)90498-4","article-title":"Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions","volume":"215","author":"Dunnett","year":"1981","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/mds.10693","article-title":"Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson\u2019s disease","volume":"19","author":"Fox","year":"2004","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","article-title":"Non-dopaminergic treatments in development for Parkinson\u2019s disease","volume":"7","author":"Fox","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/ana.20085","article-title":"Preoperative response to levodopa is the best predictor of transplant outcome","volume":"55","author":"Freed","year":"2004","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","article-title":"Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease","volume":"344","author":"Freed","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ana.410380307","article-title":"Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson\u2019s disease","volume":"38","author":"Freeman","year":"1995","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.expneurol.2011.09.017","article-title":"Extent of pre-operative l-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation","volume":"232","author":"Garcia","year":"2011","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib29","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nbd.2011.05.004","article-title":"Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and l-DOPA-induced dyskinesia","volume":"43","author":"Garcia","year":"2011","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(70)90002-4","article-title":"Combined treatment of parkinsonism with l-dopa and amantadine","volume":"2","author":"Godwin-Austen","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nn863","article-title":"Dyskinesias following neural transplantation in Parkinson\u2019s disease","volume":"5","author":"Hagell","year":"2002","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib32","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/mds.21768","article-title":"Deep brain stimulation in Parkinson\u2019s disease following fetal nigral transplantation","volume":"23","author":"Herzog","year":"2008","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-3565(25)12836-X","article-title":"Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization","volume":"277","author":"Iyer","year":"1996","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.expneurol.2004.10.002","article-title":"A\u00a0simple rodent assay for the in\u00a0vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson\u2019s disease","volume":"191","author":"Johnston","year":"2005","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF00310515","article-title":"Amphetamine, apomorphine and investigatory behavior in the rat: analysis of the structure and pattern of responses","volume":"88","author":"Kelley","year":"1986","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1471-4159.2010.06776.x","article-title":"Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson\u2019s disease","volume":"114","author":"Kobylecki","year":"2010","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib37","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2217\/rme.10.42","article-title":"Understanding graft-induced dyskinesia","volume":"5","author":"Lane","year":"2010","journal-title":"Regenerative Medicine"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.expneurol.2009.04.010","article-title":"Priming for l-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats","volume":"219","author":"Lane","year":"2009","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nbd.2005.11.011","article-title":"The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat","volume":"22","author":"Lane","year":"2006","journal-title":"Neurobiology of Disease"},{"issue":"7","key":"10.1016\/j.neuropharm.2012.06.011_bib40","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/brain\/123.7.1365","article-title":"Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease","volume":"123","author":"Lee","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib41","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/npp.2009.74","article-title":"Differential involvement of D1 and D2 dopamine receptors in l-DOPA-induced angiogenic activity in a rat model of Parkinson\u2019s disease","volume":"34","author":"Lindgren","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib42","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archneur.1989.00520420033021","article-title":"Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson\u2019s disease. A detailed account of methodology and a 6-month follow-up","volume":"46","author":"Lindvall","year":"1989","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson\u2019s disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","article-title":"Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia","volume":"194","author":"Lundblad","year":"2005","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib45","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ana.10359","article-title":"Dyskinesia after fetal cell transplantation for parkinsonism: a PET study","volume":"52","author":"Ma","year":"2002","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib46","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/jnnp.70.4.554","article-title":"High dose naltrexone for dyskinesias induced by levodopa","volume":"70","author":"Manson","year":"2001","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib47","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nbd.2005.07.002","article-title":"Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats","volume":"21","author":"Maries","year":"2006","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000098608","article-title":"Transplantation of fetal mesencephalic tissue in Parkinson\u2019s patients","volume":"62","author":"Markham","year":"1994","journal-title":"Stereotactic and Functional Neurosurgery"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib49","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00702-009-0231-z","article-title":"Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study","volume":"116","author":"Meco","year":"2009","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson\u2019s disease","volume":"101","author":"Mela","year":"2007","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib51","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/0028-3908(95)00112-3","article-title":"Effects of selective activation of the 5-HT1B receptor with CP-94,253 on sleep and wakefulness in the rat","volume":"34","author":"Monti","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.brainresbull.2004.10.011","article-title":"Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists","volume":"68","author":"Monville","year":"2005","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib53","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s00210-004-0921-x","article-title":"Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in\u00a0vivo activity of tyrosine and tryptophan hydroxylase in the rat brain","volume":"369","author":"Moranta","year":"2004","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib54","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.expneurol.2007.07.021","article-title":"Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson\u2019s disease: role of CB(1) and TRPV1 receptors","volume":"208","author":"Morgese","year":"2007","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib55","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia","volume":"131","author":"Munoz","year":"2008","journal-title":"Brain: a Journal of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib56","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","article-title":"A\u00a0double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease","volume":"54","author":"Olanow","year":"2003","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib57","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.neuropharm.2010.01.003","article-title":"MK-801 inhibits l-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism","volume":"58","author":"Paquette","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/WNR.0b013e3282f3b0d1","article-title":"Sigma ligands, but not N-methyl-d-aspartate antagonists, reduce levodopa-induced dyskinesias","volume":"19","author":"Paquette","year":"2008","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.neuropharm.2012.06.011_bib59","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/brain\/117.3.487","article-title":"Bilateral motor improvement and alteration of l-dopa effect in two patients with Parkinson\u2019s disease following intrastriatal transplantation of foetal ventral mesencephalon","volume":"117","author":"Peschanski","year":"1994","journal-title":"Brain: a Journal of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib60","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/16060","article-title":"Dopamine release from nigral transplants visualized in\u00a0vivo in a Parkinson\u2019s patient","volume":"2","author":"Piccini","year":"1999","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/mds.23743","article-title":"Graft-induced dyskinesias in Parkinson\u2019s disease: high striatal serotonin\/dopamine transporter ratio","author":"Politis","year":"2011","journal-title":"Movement Disorders"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000976","article-title":"Serotonergic neurons mediate dyskinesia side effects in Parkinson\u2019s patients with neural transplants","volume":"2","author":"Politis","year":"2010","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/107385802237703","article-title":"Cellular replacement therapy for Parkinson\u2019s disease\u2013where we are today?","volume":"8","author":"Redmond","year":"2002","journal-title":"The Neuroscientist: a Review Journal Bringing Neurobiology, Neurology and Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib64","first-page":"325","article-title":"Cellular replacement of dopamine deficit in Parkinson\u2019s disease using human fetal mesencephalic tissue: preliminary results in four patients","volume":"71","author":"Redmond","year":"1993","journal-title":"Research Publications \u2013 Association for Research in Nervous and Mental Disease"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib65","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A\u00a0mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of l-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib67","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neuropharm.2012.06.011_bib68","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bbr.2012.04.003","article-title":"Amphetamine-induced rotation in the transplanted hemi-parkinsonian rat \u2013 Response to pharmacological modulation","volume":"232","author":"Smith","year":"2012","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib69","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/mds.10588","article-title":"Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats","volume":"18","author":"Steece-Collier","year":"2003","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cne.22037","article-title":"Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats","volume":"515","author":"Steece-Collier","year":"2009","journal-title":"The Journal of Comparative Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib71","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","article-title":"D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons","volume":"30","author":"Surmeier","year":"2007","journal-title":"Trends in Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib72","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.neuroscience.2008.03.048","article-title":"Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson\u2019s disease","volume":"154","author":"Torres","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib73","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.euroneuro.2006.04.009","article-title":"Amphetamine induced rotation in the assessment of lesions and grafts in the unilateral rat model of Parkinson\u2019s disease","volume":"17","author":"Torres","year":"2007","journal-title":"European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jneumeth.2011.06.012","article-title":"Increased efficacy of the 6-hydroxydopamine lesion of the median forebrain bundle in small rats, by modification of the stereotaxic coordinates","volume":"200","author":"Torres","year":"2011","journal-title":"Journal of Neuroscience Methods"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib75","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jneumeth.2006.05.016","article-title":"An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections","volume":"158","author":"Torres","year":"2006","journal-title":"Journal of Neuroscience Methods"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib76","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1046\/j.1471-4159.2003.02109.x","article-title":"Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing","volume":"87","author":"Venton","year":"2003","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib77","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1093\/brain\/awn192","article-title":"Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON l-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson\u2019s disease","volume":"131","author":"Vinuela","year":"2008","journal-title":"Brain: a Journal of Neurology"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib78","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.brainresbull.2010.01.009","article-title":"Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson\u2019s disease in the rat","volume":"81","author":"Walsh","year":"2010","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib79","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1046\/j.0953-816x.2001.01743.x","article-title":"Persistent changes in striatal gene expression induced by long-term l-DOPA treatment in a rat model of Parkinson\u2019s disease","volume":"14","author":"Westin","year":"2001","journal-title":"European Journal Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib80","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","article-title":"Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors","volume":"62","author":"Westin","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib81","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0306-4522(03)00007-1","article-title":"Regulation of neuropeptide mRNA expression in the basal ganglia by intrastriatal and intranigral transplants in the rat Parkinson model","volume":"118","author":"Winkler","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.06.011_bib82","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson\u2019s disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiology of Disease"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390812002699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T17:25:26Z","timestamp":1743528326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390812002699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0028390812002699"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.011","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}